Ademi LLP is investigating One Medical (NASDAQ: ONEM) for possible breaches of fiduciary duty and other violations of law in its transaction with Amazon.
Ademi LLP alleges One Medical’s financial outlook and prospects are excellent and yet One Medical holders will receive only $18 per share in an all-cash transaction valued at approximately $3.9 billion, including One Medical’s net debt. The transaction agreement unreasonably limits competing bids for One Medical by imposing a significant penalty if One Medical accepts a superior bid. One Medical insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of One Medical’s board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for One Medical.